Finance entity
All 2 tracked stories fall under one category: earnings. Supernus Pharmaceuticals is most often covered alongside Axon Enterprise, which appears in 1 of these 2 stories. Each story carries 5 original sources on average, compared with 2.6 for the broader beat in this window.
Last mentioned: Aug 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: earnings. Supernus Pharmaceuticals is most often covered alongside Axon Enterprise, which appears in 1 of these 2 stories. Each story carries 5 original sources on average, compared with 2.6 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 6. Supernus Pharmaceuticals appears in 2 tracked Finance stories published from February 23, 2026 through February 26, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 358 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Supernus Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
A wave of Q4 2025 earnings reports from mid-cap leaders across healthcare, automotive, and retail sectors highlights a bifurcated recovery. While MedTech and high-end retail show margin expansion, the EV and industrial sectors continue to navigate significant production and scaling headwinds.
Axon Enterprise is set to report Q4 2025 results, with investors focused on the adoption of AI-driven tools like Draft One and the continued rollout of TASER 10. Meanwhile, specialty pharma players Corcept and Supernus prepare to disclose their own year-end performance amid shifting regulatory and competitive landscapes.
Supernus Pharmaceuticals is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
